SIGY.US Sigyn Therapeutics Inc

Healthcare Biotechnology USA Stocks
0.0270 USD
Close of Nov 17, 2026
0.0100 2.00
Market cap
USD 146K
P/E
-
P/B
39.04x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2025.

Is SIGY.US undervalued?

Graham number

The Graham number of Sigyn Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sigyn Therapeutics Inc fundamental analysis

No fundamental analysis for Sigyn Therapeutics Inc yet.

Sigyn Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sigyn Therapeutics Inc

Sigyn Therapeutics, Inc., a development-stage company, develops and sells medical devices to treat cancer and infectious disease disorders in the United States. Its lead product candidate is Sigyn therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community-acquired pneumonia, drug-resistant bacterial infections, and emerging …

Full company profile